Search results
This edition includes exciting news about our Annual and Professionals’ Conferences. We hope as many of you as possible can join us in Manchester, or online, in September. You’ll also find updates about the latest research and a feature on one of our funded researchers, Dr Jörn Lakowski.
Inside this edition, set yourself a challenge in 2024, plus find out about our brand new lottery.
Friday 23 May, 5.30pm - 9.30pm - In-person - Come and join Bhavini and the group for their latest outing to see an audio described performance of The Play That Goes Wrong at the Duchess Theatre in London.
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
This page explains the different types of genetic tests: diagnostic testing, predictive testing, carrier testing and research testing
Prof Mariya Moosajee at Moorfields Eye Hospital has asked us to share the message below about the clinical trial she is running. This trial is for a treatment that targets a particular section of the USH2A gene.
Choroideremia is a rare genetic condition resulting in progressive sight loss in men.
The project aims to develop a cost effective method of examining the entire ABCA4 gene to look for variations that might cause disease.
Sepul Bio begins clinical trial of ultevursen for USH2A-associated RP
Jing Yu is a bioinformatician with the Eye Research Group at Oxford University, and is part of the UK Inherited Retinal Dystrophy Consortium (UKIRDC) team, funded by a Retina UK grant.
